Justin Walsh
Stock Analyst
(3.18)
# 833
Out of 4,648 analysts
31
Total ratings
41.38%
Success rate
4.95%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $23.62 | +77.82% | 1 | Oct 18, 2024 | |
| THTX Theratechnologies | Downgrades: Hold | n/a | $1.19 | - | 2 | Oct 11, 2024 | |
| BLRX BioLineRx | Initiates: Buy | $2 | $0.43 | +368.06% | 1 | Sep 4, 2024 | |
| LNTH Lantheus Holdings | Maintains: Buy | $105 → $146 | $115.45 | +26.46% | 7 | Jul 25, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $23 | $14.87 | +54.67% | 1 | Jul 11, 2024 | |
| CATX Perspective Therapeutics | Maintains: Buy | $15 → $22 | $12.19 | +80.48% | 2 | May 16, 2024 | |
| TLSI TriSalus Life Sciences | Initiates: Buy | $16 | $3.98 | +302.01% | 1 | May 10, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $20 | $4.74 | +321.94% | 1 | Apr 17, 2024 | |
| CTSO Cytosorbents | Reinstates: Buy | $4 | $0.87 | +359.51% | 4 | Sep 7, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $20 | $3.96 | +405.05% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $0.78 | +2,207.69% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $175 | $1.90 | +9,110.53% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $0.24 | +4,464.32% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $1.36 | +5,414.30% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $45.83 | -56.36% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $4.33 | +4,518.94% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.70 | +488.24% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $800 | $5.01 | +15,868.06% | 1 | Sep 2, 2021 |
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $23.62
Upside: +77.82%
Theratechnologies
Oct 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.19
Upside: -
BioLineRx
Sep 4, 2024
Initiates: Buy
Price Target: $2
Current: $0.43
Upside: +368.06%
Lantheus Holdings
Jul 25, 2024
Maintains: Buy
Price Target: $105 → $146
Current: $115.45
Upside: +26.46%
Y-mAbs Therapeutics
Jul 11, 2024
Initiates: Buy
Price Target: $23
Current: $14.87
Upside: +54.67%
Perspective Therapeutics
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $12.19
Upside: +80.48%
TriSalus Life Sciences
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $3.98
Upside: +302.01%
Achieve Life Sciences
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $4.74
Upside: +321.94%
Cytosorbents
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $0.87
Upside: +359.51%
Prime Medicine
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $3.96
Upside: +405.05%
May 16, 2023
Initiates: Buy
Price Target: $18
Current: $0.78
Upside: +2,207.69%
Mar 22, 2023
Initiates: Buy
Price Target: $175
Current: $1.90
Upside: +9,110.53%
Feb 10, 2023
Initiates: Buy
Price Target: $11
Current: $0.24
Upside: +4,464.32%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $1.36
Upside: +5,414.30%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $45.83
Upside: -56.36%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $4.33
Upside: +4,518.94%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $1.70
Upside: +488.24%
Sep 2, 2021
Initiates: Buy
Price Target: $800
Current: $5.01
Upside: +15,868.06%